Pull to refresh
Logo
GLP-1 drugs prove they protect the heart

GLP-1 drugs prove they protect the heart

New Capabilities

Real-world data and a large trial show tirzepatide lowers heart attacks, strokes, and cardiovascular death in diabetes patients

2 days ago: Real-world data confirm the benefit

Overview

About 53,000 Americans with type 2 diabetes and heart disease were tracked through their insurance records. Those who started tirzepatide had a 2.9% risk of a heart attack, stroke, or cardiovascular death within a year, against 4.4% for a comparison drug.

Tirzepatide is sold as Mounjaro for diabetes and Zepbound for weight loss. The Harvard study, published in The BMJ, backs up a large randomized trial from December: a drug taken for blood sugar and weight also guards the heart.

Why it matters

Heart disease is the top killer of people with type 2 diabetes, and drugs millions already take for weight and blood sugar now cut that risk too.

Questions about this story

No questions yet — be the first to ask.

Key Indicators

52,971
Adults in the real-world study
U.S. patients with type 2 diabetes, obesity or overweight, and established heart disease.
2.9%
1-year heart-event risk on tirzepatide
Compared with 4.4% for sitagliptin, a drug with no known heart effect.
13,165
Patients in the SURPASS-CVOT trial
The randomized trial across 30 countries that this study confirms.
16%
Lower all-cause mortality vs dulaglutide
SURPASS-CVOT result for tirzepatide against an older GLP-1 drug.
20%
Heart-event drop with semaglutide
The 2023 SELECT trial that opened this line of evidence.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Play

Exploring all sides of a story is often best achieved with Play.

Most of these play right now — no account needed. Sign up to save scores, keep a streak, and unlock Debate and Predict. Log in Sign Up
Predict 4 ways this could play out. Back the one you believe — contrarian picks score more when a scenario has a resolution date. Log in to play

People Involved

Organizations Involved

Timeline

June 2016 August 2026

5 events Latest: 2 days ago
Tap a bar to jump to that date
  1. Real-world data confirm the benefit

    Latest Study

    A Harvard analysis in The BMJ finds tirzepatide users had a 2.9% one-year heart-event risk versus 4.4% on sitagliptin.

  2. SURPASS-CVOT published

    Clinical Trial

    Tirzepatide matches dulaglutide on heart events and lowers all-cause deaths by 16% across 13,165 patients in 30 countries.

  3. FDA approves a heart claim

    Regulatory

    The FDA clears semaglutide (Wegovy) to reduce cardiovascular risk, the first of these drugs to earn the label.

  4. SELECT trial changes the picture

    Clinical Trial

    Semaglutide cuts major heart events by 20% in overweight or obese patients with heart disease and no diabetes.

  5. First GLP-1 heart benefit

    Clinical Trial

    The LEADER trial shows liraglutide (Victoza) cuts heart events in diabetes patients, the first GLP-1 drug to do so.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

May 2007

Rosiglitazone safety scare (2007)

Cardiologist Steven Nissen published a meta-analysis linking the diabetes pill rosiglitazone (Avandia) to a 43% higher risk of heart attack. Prescriptions and sales fell sharply.

Then

The FDA added strong warnings and heavily restricted the drug's use.

Now

In 2008 the FDA began requiring new diabetes drugs to prove they do not raise heart risk, making the cardiovascular outcome trial a standard hurdle.

Why this matters now

That mandate is why tirzepatide was tested against the heart at all. A rule meant to catch harm now surfaces benefit.

September 2015

EMPA-REG OUTCOME trial (2015)

A trial of the diabetes drug empagliflozin in 7,020 patients found it cut death from cardiovascular causes by 38%, a result few expected from a blood-sugar drug.

Then

Guidelines moved SGLT2 inhibitors toward the front line for diabetes patients with heart disease.

Now

It reset expectations, showing a diabetes drug could actively protect the heart rather than merely avoid harm.

Why this matters now

Tirzepatide follows the same path from metabolic drug to heart drug, changing how doctors pick diabetes treatments.

November 1994

Scandinavian Simvastatin Survival Study (1994)

The 4S trial followed 4,444 heart patients and found simvastatin cut deaths by 30%, proving cholesterol drugs prevent heart attacks.

Then

Statins became standard care for people with heart disease.

Now

It made long-term preventive medication routine for hundreds of millions of people.

Why this matters now

GLP-1 drugs may trace the statin arc: a drug class that starts targeted and ends up widely prescribed to prevent heart events.

Sources

(7)